Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - ThinkEquity LLC initiates coverage of Durect Corp: Buy Rating, $3 price target; $DRRX

Daily Dose Newsroom Index

Top

Search Daily Dose & Film Annex

BIO SmartBrief

Daily Dose Newsletter

Friday

Mar232012

ThinkEquity LLC initiates coverage of Durect Corp: Buy Rating, $3 price target; $DRRX

DDE Editor

Durect Corporation (DRRX) is a specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER™ Delivery System (a patented and versatile depot injectable useful for proteins, peptides and small molecule delivery), the ORADUR® sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the TRANSDUR® transdermal patch technology, the DURIN™ Biodegradable Implant (drug-loaded implant system) and the MICRODUR™ Biodegradable Microparticulates (microspheres injectable system).

DURECT also partners with pharmaceutical and biotechnology companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has seven disclosed on-going development programs of which six are in collaboration with pharmaceutical partners.

Daily Dose Thoughts: Durect has been around forever but the company seems to be making great progress in perfecting their drug delivery technology. With top line revenues and a solid balkance sheet and several catalysts that can play out ahead. This is a cheap biotech with a few shots on goal in potentially large indications.

ThinkEquity LLC has initiated coverage of Durect Corp, giving it a "Buy" rating and a $3 price target.

The report states,

"While DRRX has had a bumpy road over the past few years in our view, we continue to see a compelling combination of large-pharma collaborations with an under valued pipeline that could provide potential upside surprise. DRRX’s lead product is Remoxy, a less-abusable Oxycontin partnered with Pfizer (PFE), which we believe could be potentially re-filed with the FDA by late 2013E. In 2H12, DRRX could file an NDA for the post-surgical pain injection Posidur, partnered with Hospira (HSP) and targeting 10M-20M US surgeries. Additionally, in ourview, DRRX has a deep pipeline of earlier pain compounds."

Read the full report below.

Think equity report on drrx

View more documents from DailyDoseEquities.

View the full DRRX chart at Wikinvest

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

Post a New Comment

Enter your information below to add a new comment.

My response is on my own website »

Author:

Author Email (optional):

Author URL (optional):

Post:

↓ | ↑

Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>

Copyright by Daily Dose Equities. All rights reserved. This website contains information and opinions based on data obtained from reliable sources, which is current as of the publication date, and does not constitute a recommendation that any of the securities mentioned herein are appropriate for any specific individual circumstances and does not guarantee that future results or performance will match those predicted to occur. Although every effort is made to ensure the accuracy and completeness of the information on this website by using reliable data sources such as SEC filings and press releases, no guarantees are made in this regard as it has not been reviewed or certified by an independent auditor and may also include the opinions and future projections of the author. The contributing authors on this website are not chartered financial analysts, registered investment advisors or broker/dealers, and do not provide individual investment advice. The information provided by the writers on this website is for informational purposes only and should not be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction. The information appearing on this website, blog, and related publications has not been reviewed or endorsed by any of the companies mentioned and should not be regarded as offical corporate news, publications, or shareholder communications. Film Annex Capital Partners, LLC (FACP) is the owner of this website and they provide strategic advisory, social media, and marketing services to emerging-growth companies. A number of the companies displayed on this site may be current or previous clients of FACP. In most instances, FACP has received fees for services for the creation, preparation and distribution of materials featured on this site, which are paid for in cash and/or stock, by the featured company ("client"). More detailed disclosure regarding fees paid is available upon request. FACP is not a broker/dealer or registered investment advisor. Information contained throughout this site is not an offer to buy or sell securities. Information presented on this site is solely for informative purposes, and is not intended, nor should they be construed, as investment advice. The information provided including news, blogs, corporate profiles, and other material is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. The companies featured on this site are typically development-stage and investment in such securities is considered highly speculative and carries a high degree of risk. Complete loss of capital is a distinct possibility. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org. Opinions stated herein may be solely FACP or the indicated source's, and not necessarily those of the featured Company. Officers, directors, and employees of FACP and financial analysts mentioned, and/or members of their families, may hold a position and may, from time to time, trade in these securities for their own accounts. Specific information in this regard will be furnished upon request. Trademarks are the property of their respective owners. 2010-12 Film Annex Capital Partners, LLC. All rights reserved.